What is AAVXF stock price today?

AAVXF (Abivax S.A.) stock is trading at $115.65 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is AAVXF stock going up or down today?

AAVXF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy AAVXF stock now?

The decision to buy AAVXF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is AAVXF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for AAVXF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is AAVXF stock overvalued or undervalued?

Use our DCF valuation calculator to determine if AAVXF is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is AAVXF's P/E ratio?

P/E ratio data for AAVXF will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is AAVXF's market cap?

AAVXF (Abivax S.A.) has a market capitalization of $9.78 billion, making it a small-cap stock.

What is AAVXF's price to book ratio?

AAVXF trades at a price-to-book (P/B) ratio of 17.06, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does AAVXF pay dividends?

AAVXF does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is AAVXF's dividend yield?

AAVXF does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is AAVXF stock a good long-term investment?

AAVXF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is AAVXF's revenue growth rate?

AAVXF has shown revenue growth of -0.6% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for AAVXF are available on our dashboard with complete income statement analysis.

What are the risks of investing in AAVXF?

Key risks for AAVXF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does AAVXF compare to its competitors?

Compare AAVXF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize AAVXF's performance and positioning.

What is AAVXF's stock price target for 2026?

Our AI model provides price targets for AAVXF based on fundamental analysis: Bull case $150.34 (+30%), Base case $133.00 (+15%), Bear case $104.09 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about AAVXF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for AAVXF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is AAVXF's next earnings report?

AAVXF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

AAVXF - Abivax S.A.

NYSE * Healthcare * Biotechnology

$115.65

+$0.00 (+0.00%)

About Abivax S.A.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

AAVXF Key Statistics

Market Cap

$9.78B

P/B Ratio

17.06

EPS

$-5.70

Revenue Growth

-0.6%

Employees

How AAVXF Compares to Peers

AAVXF is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
AAVXF(This stock)	$9.78B	N/A	-1%	0.0%	-
AMGNAmgen Inc	$188.76B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$168.64B	20.0	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$111.71B	28.6	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.23B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.91B	20.9	-0%	0.1%	vs BIIB

Abivax S.A. Company Information

Headquarters: 7-11 Boulevard Haussmann, Paris, France, 75009, undefined
Website: www.abivax.com
Sector: Healthcare
Industry: Biotechnology

Data Updated: April 21, 2026 at 11:13 PM EDT

Ready to invest in AAVXF?

Commission-free trading available. Affiliate links.

Upcoming Events for AAVXF

Dashboard

Enter a ticker to analyze